January 13, 2022
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
Related Posts
-
C-Path Appoints Key Scientific Leaders to Executive Roles -
Register Now | Clinical Outcome Assessments: Does one size fit all?
-
The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs -
Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature -
C-Path Welcomes BioCentury Inc. Co-Founder Bernstein to Board of Directors